These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9327320)

  • 1. Indicators of fibrinolysis during cardiopulmonary bypass after exogenous antithrombin-III administration for acquired antithrombin III deficiency.
    Van Norman GA; Gernsheimer T; Chandler WL; Cochran RP; Spiess BD
    J Cardiothorac Vasc Anesth; 1997 Oct; 11(6):760-3. PubMed ID: 9327320
    [No Abstract]   [Full Text] [Related]  

  • 2. Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations.
    Petăjă J; Peltola K; Sairanen H; Leijala M; Kekomäki R; Vahtera E; Siimes MA
    J Thorac Cardiovasc Surg; 1996 Sep; 112(3):665-71. PubMed ID: 8800154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of coagulation and fibrinolysis during cardiothoracic operations.
    Hunt BJ; Parratt RN; Segal HC; Sheikh S; Kallis P; Yacoub M
    Ann Thorac Surg; 1998 Mar; 65(3):712-8. PubMed ID: 9527200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
    Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
    Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital and acquired antithrombin III deficiency.
    Nakagawa M; Tsuji H; Maebo N; Toyoda T; Sawada S; Takamatsu H; Ijichi H
    Nihon Ketsueki Gakkai Zasshi; 1985 Dec; 48(8):1885-94. PubMed ID: 3836551
    [No Abstract]   [Full Text] [Related]  

  • 6. Prophylactic antithrombotic therapy with stanozolol in patients with familial antithrombin III deficiency.
    Winter JH; Fenech A; Bennett B; Douglas AS
    Br J Haematol; 1984 Jul; 57(3):527-37. PubMed ID: 6743570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication.
    Tohgi H; Takahashi H; Chiba K; Tamura K
    Stroke; 1993 Jun; 24(6):801-4. PubMed ID: 8506551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery.
    Spiess BD; Vocelka C; Cochran RP; Soltow L; Chandler WL
    J Cardiothorac Vasc Anesth; 1998 Jun; 12(3):299-304. PubMed ID: 9636912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass.
    Khuri SF; Valeri CR; Loscalzo J; Weinstein MJ; Birjiniuk V; Healey NA; MacGregor H; Doursounian M; Zolkewitz MA
    Ann Thorac Surg; 1995 Oct; 60(4):1008-14. PubMed ID: 7574939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass.
    Tabuchi N; de Haan J; Boonstra PW; van Oeveren W
    J Thorac Cardiovasc Surg; 1993 Nov; 106(5):828-33. PubMed ID: 8231204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical treatment of atrial septal defect in a patient with familial antithrombin-III deficiency.
    Hattori T; Hata M; Sezai A; Wakui S; Shiono M
    Ann Thorac Cardiovasc Surg; 2013; 19(4):323-5. PubMed ID: 23232305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired antithrombin III deficiency: replacement with antithrombin III concentrates in a patient with protein S deficiency accelerates response to therapy.
    Humphries JE
    Acta Haematol; 1993; 90(3):151-4. PubMed ID: 8291376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacologic aspects of thrombophilia].
    Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):535-49. PubMed ID: 6083924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial antithrombin-III deficiency during cardiopulmonary bypass: a case report.
    Brinks HJ; Weerwind PW; Verkroost MW; Nováková I; Brouwer MH
    Perfusion; 2000 Nov; 15(6):553-6. PubMed ID: 11131221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the coagulation and fibrinolytic systems during and after cardiopulmonary bypass surgery.
    Kongsgaard UE; Smith-Erichsen N; Geiran O; Bjørnskau L
    Thorac Cardiovasc Surg; 1989 Jun; 37(3):158-62. PubMed ID: 2527423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombin III. Key factor in extracorporeal circulation.
    Ranucci M
    Minerva Anestesiol; 2002 May; 68(5):454-7. PubMed ID: 12029263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of coagulation factor activation during cardiopulmonary bypass with a new monoclonal antibody.
    Journois D; Mauriat P; Pouard P; Marchot P; Amiral J; Safran D
    J Cardiothorac Vasc Anesth; 1994 Apr; 8(2):157-61. PubMed ID: 8204808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery.
    Kojima T; Gando S; Morimoto Y; Mashio H; Goda Y; Kawahigashi H; Kemmotsu O
    Thromb Res; 2001 Dec; 104(5):301-7. PubMed ID: 11738071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin anticoagulation during cardiopulmonary bypass in an antithrombin-III deficient patient. Implications relative to the etiology of heparin rebound.
    Soloway HB; Christiansen TW
    Am J Clin Pathol; 1980 May; 73(5):723-5. PubMed ID: 7377145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombin deficiency in special clinical syndromes--Part II: cardiovascular surgery.
    Levy JH
    Semin Hematol; 1995 Oct; 32(4 Suppl 2):49-55. PubMed ID: 8821210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.